Compare Appian Corp (APPN) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs Summit Therapeutics Inc — how do they compare? Appian Corp trades at $35.5 (market cap $2.54B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 4.7× Appian Corp's market cap, and Appian Corp is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| APPN | SMMT | |
|---|---|---|
Market Cap | $2.54B | $12.06B |
Sector | Technology | Health |
52-Week High | $45.64 | $26.98 |
52-Week Low | $18.72 | $12.55 |
Enterprise Value | $2.67B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian (APPN) trades at $34.82, down 2.14% on the day despite strong technical momentum. The stock shows bullish moving average signals but overbought RSI readings. Fundamentally, the company delivered three consecutive earnings beats with Q2 2026 EPS of $0.13 beating expectations of $0.00308, while revenue grew 19% year-over-year to $203.3 million. Recent news highlights AI-powered underwriting partnerships and strong enterprise demand driving growth.
Appian presents a mixed investment case with strong revenue growth and AI momentum offset by negative profitability metrics and elevated valuations. The stock trades above analyst consensus target of $32.50, suggesting limited near-term upside. Key risks include persistent negative ROE (-936.62%) and high debt levels, though improving cash flow and AI adoption provide growth catalysts.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
